Remove tag silico
article thumbnail

AI is critical to solving new complexities in drug discovery

Drug Discovery World

It also carries a much higher price tag for failure. Utilising AI, it is possible to build in silico models of any disease using dozens of heterogenous, human-derived data sources, then integrating potential treatments against that data in one process, breaking that data silo we face in traditional drug discovery avenues.

Drugs 52
article thumbnail

What to expect from PEGS Europe 2023: Day 3

Drug Discovery World

Mitja Zidar, PhD, Senior Expert Science and Technology, Novartis, on: ‘Analytical characterisation meets molecular modeling: In silico forced degradation studies’. Fabian Mohr, PhD, Vice President Research & Development, IBA Lifesciences, on: ‘Developing a robust affinity tag platform using engineered streptavidin’.

Protein 59